Sign in

    Alex Vukasin

    Vice President and Healthcare Senior Associate Equity Research Analyst at Canaccord Genuity - Global Capital Markets

    Alex Vukasin is a Vice President and Healthcare Senior Associate Equity Research Analyst at Canaccord Genuity - Global Capital Markets, specializing in coverage of diagnostics and life science tools companies such as Biodesix. Since joining Canaccord Genuity in 2021, he has played a key role in tracking sector trends and providing actionable insights for institutional clients, demonstrating leadership in the healthcare vertical. Vukasin holds an undergraduate degree from Princeton University and has previously held analytical and advisory roles at Lord Abbett & Co., Westwicke Partners, and Edgestream Partners. He is a FINRA-registered broker, holding requisite securities industry licenses for his position.

    Alex Vukasin's questions to GRAIL (GRAL) leadership

    Alex Vukasin's questions to GRAIL (GRAL) leadership • Q2 2025

    Question

    Alex Vukasin of Canaccord Genuity inquired about GRAIL's Q2 cash burn and the key dynamics expected to impact the burn rate in the second half of 2025.

    Answer

    CFO Aaron Freidin noted a first-half burn of approximately $160 million and projected a decrease in the second half, driven by higher volumes, increased revenue, and greater efficiency from the new automated platform. CEO Bob Ragusa added that the company's restructuring provided flexibility, leading to an improved full-year cash burn guidance of no more than $310 million.

    Ask Fintool Equity Research AI

    Alex Vukasin's questions to BIODESIX (BDSX) leadership

    Alex Vukasin's questions to BIODESIX (BDSX) leadership • Q2 2025

    Question

    Alex Vukasin, on behalf of Kyle Mixon from Canaccord Genuity, asked about the long-term potential volume mix between primary care physicians and pulmonologists. He also inquired about the expected timing and impact of the HEDIS quality measures for lung cancer screening.

    Answer

    Scott Hutton, President, CEO & Director, responded that it is too early to forecast a specific long-term volume mix, as the strategy is to follow pulmonologist referrals. Regarding HEDIS, Hutton stated the measures have been put on hold for the year due to cited complexities. He noted this delays a potential tailwind but does not impact the company's 2025 or 2026 forecasts.

    Ask Fintool Equity Research AI